Skip to main content
Medical information Clinical review pending

Transplant Testing

HLA Pretransplant Workup Non Sensitized Recipient Panel1 Test

This test assesses compatibility for organ transplantation by analyzing HLA profiles. It helps predict potential immune responses and improve transplant success rates.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Recipient: 6 mL (3 mL min.) whole blood in 1 Yellow Top (ACD) tube AND 3 mL (2 mL min.) serum from 1 SST AND 4 mL (2 mL min.) whole blood in 1 Lavender top (EDTA) tube. Collect specimen preferably 48 hours after dialysis. Ship refrigerated. DO NOT FREEZE. A doctor's prescription on the letterhead with 1 photograph each of recipient and donor duly stamped AND a Consent form for HLA Typing for Solid organ transplant (Form 33) is mandatory.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is required for the blood draw. Please follow any specific instructions provided by your doctor or the transplant center. Ensure the specimen is collected as directed, preferably 48 hours after dialysis if applicable.
Test priceKSh 44,460

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the HLA Pretransplant Workup Non Sensitized Recipient Panel1 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals preparing for a kidney transplant.
  • ✓Individuals preparing for a liver transplant.
  • ✓Patients undergoing evaluation for organ donation compatibility.
  • ✓Assessing potential immune responses before transplantation.
02

In plain language

What this test helps you understand

This test is used to assess the compatibility between a potential organ recipient and donor, helping to predict the risk of transplant rejection and guide donor selection for kidney or liver transplants.
The HLA Pretransplant Workup Non Sensitized Recipient Panel1 Test is a crucial part of the evaluation process before an organ transplant, particularly for kidney or liver recipients. It helps determine how well a potential donor's organ matches the recipient's immune system. Understanding this compatibility is vital because mismatches can lead to the recipient's body rejecting the new organ. This test provides essential information to medical teams to make the best decisions for a successful transplant outcome. It involves analyzing specific genetic markers called Human Leukocyte Antigens (HLA) in both the recipient and potential donor.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for the blood draw. Please follow any specific instructions provided by your doctor or the transplant center. Ensure the specimen is collected as directed, preferably 48 hours after dialysis if applicable.
SampleRecipient: 6 mL (3 mL min.) whole blood in 1 Yellow Top (ACD) tube AND 3 mL (2 mL min.) serum from 1 SST AND 4 mL (2 mL min.) whole blood in 1 Lavender top (EDTA) tube. Collect specimen preferably 48 hours after dialysis. Ship refrigerated. DO NOT FREEZE. A doctor's prescription on the letterhead with 1 photograph each of recipient and donor duly stamped AND a Consent form for HLA Typing for Solid organ transplant (Form 33) is mandatory.
MethodologyThe test involves HLA DNA typing (PCR Low resolution Luminex), HLA T & B cell lymphocyte crossmatch, and HLA Panel Reactive IgG antibodies (PRA) Screen Luminex.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test assesses specific HLA markers. Other factors can also influence transplant success. Results should be interpreted in the context of the patient's overall health and clinical picture.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

HLA typing identifies specific proteins on the surface of cells that are unique to each individual. These proteins help the immune system distinguish between the body's own cells and foreign cells.
Matching HLA types between donor and recipient reduces the risk of the recipient's immune system attacking the transplanted organ, which is known as rejection.
This refers to recipients who have not previously developed antibodies against HLA antigens, typically due to prior transplants, blood transfusions, or pregnancies.
Mismatches may increase the risk of rejection. Your transplant team will use this information, along with other factors, to decide on the best course of action, which might include finding a different donor or using immunosuppressive medications.
A doctor's prescription on letterhead with photos of recipient and donor, stamped, and a completed Consent form for HLA Typing for Solid organ transplant (Form 33) are required.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp